TY - JOUR
T1 - Crystal structure of human catecholamine sulfotransferase
AU - Bidwell, Lisa M.
AU - McManus, Michael E.
AU - Gaedigk, Andrea
AU - Kakuta, Yoshimitsu
AU - Negishi, Masa
AU - Pedersen, Lars
AU - Martin, Jennifer L.
N1 - Funding Information:
We thank Alun Jones for help with mass spectrometric data measurement and analysis, Dr Luke Guddat for help with X-ray data measurement and Joel Tyndall for help with Figures. We also acknowledge Dr Elizabeth Gillam for advice on the purification of SULT1A3. The SULT1A3 research is supported by grants from the National Health and Medical Research Council of Australia and the University of Queensland (Mayne Bequest Fund). This work is based on research conducted at the Stanford Synchrotron Radiation Laboratory (SSRL), which is funded by the Department of Energy, Office of Basic Energy Sciences. The SSRL Biotechnology Program is supported by the National Institutes of Health, National Centre for Research Resources, Biomedical Technology Program and the Department of Energy, Office of Biological and Environmental Research. J.L.M. is supported by an Australian Research Council Fellowship.
PY - 1999/10/29
Y1 - 1999/10/29
N2 - Sulfonation, like phosphorylation, can modify the activity of a variety of biological molecules. The sulfotransferase enzymes sulfonate neurotransmitters, drugs, steroid hormones, dietary carcinogens and proteins. SULT1A3 specifically sulfonates catecholamines such as dopamine, adrenaline and noradrenaline. The crystal structure of SULT1A3 with a sulfate bound at the active site, has been determined at 2.4 Å resolution. Although the core α/β fold is like that of estrogen and heparan sulfotransferases, major differences occur in and around the active site. Most notably, several regions surrounding the active site, including a section of 40 residues, are disordered in SULT1A3. Regions that are topologically equivalent to the disordered parts of SULT1A3 are involved in substrate and cofactor binding in estrogen and heparan sulfotransferase. Flexibility in these regions suggests that ligand binding elicits a disorder-order transition in and around the active site of sulfotransferases and might contribute to the broad substrate specificity of these enzymes.
AB - Sulfonation, like phosphorylation, can modify the activity of a variety of biological molecules. The sulfotransferase enzymes sulfonate neurotransmitters, drugs, steroid hormones, dietary carcinogens and proteins. SULT1A3 specifically sulfonates catecholamines such as dopamine, adrenaline and noradrenaline. The crystal structure of SULT1A3 with a sulfate bound at the active site, has been determined at 2.4 Å resolution. Although the core α/β fold is like that of estrogen and heparan sulfotransferases, major differences occur in and around the active site. Most notably, several regions surrounding the active site, including a section of 40 residues, are disordered in SULT1A3. Regions that are topologically equivalent to the disordered parts of SULT1A3 are involved in substrate and cofactor binding in estrogen and heparan sulfotransferase. Flexibility in these regions suggests that ligand binding elicits a disorder-order transition in and around the active site of sulfotransferases and might contribute to the broad substrate specificity of these enzymes.
UR - http://www.scopus.com/inward/record.url?scp=0032740346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032740346&partnerID=8YFLogxK
U2 - 10.1006/jmbi.1999.3153
DO - 10.1006/jmbi.1999.3153
M3 - Article
C2 - 10543947
AN - SCOPUS:0032740346
SN - 0022-2836
VL - 293
SP - 521
EP - 530
JO - Journal of Molecular Biology
JF - Journal of Molecular Biology
IS - 3
ER -